WhatÕs new in dementia this week
Ireland:
Dementia in the media this week
1.
ÔHSE to establish
register to help people with dementia
2.
ÔThe screaming will go
on for hours until she falls asleep' - Ex-Mrs Brown's Boys star Rory Cowan on
coping with his mother's dementiaÕ
3. Ô10 things to know about dementia
http://www.independent.ie/life/health-wellbeing/10-things-to-know-about-dementia-36158539.html
4. ÔLiving well with dementia strategy
5.
Alzheimer Society of Ireland advocates Helen Rochford Brennan and Sean D—nal OÕ
Shea speak on RTEÕs The Today Show.
Watch their interview here https://www.rte.ie/player/ie/show/today-with-maura-and-daithi-30001768/10781255/ (Interview begins at 1.09.17)
Ireland:
Upcoming Events
1.
DDNI Conference November 30th 2017
The Dementia and
Neurodegeneration Network Ireland (DNNI), in partnership with the Alzheimer
Society of Ireland and SPHeRE, will host their inaugural conference on 'Building Platforms for Sustainable Research
in Dementia and Neurodegeneration'.
The conference wil be
held on November 30th 2017 in the Dining Hall at Kings InnÕs, Dublin
1.
To register please see https://www.eventbrite.ie/e/dnni-conference-2017-tickets-37728733658
2. Dementia Masterclass November 27th-29th
2017
The Centre for
Economic and Social Research on Dementia at NUI Galway are hosting a three
day Dementia Masterclass from 27-29th November in NUI Galway. The
event is supported by the GBHI and the University of California, San
Francisco.
Places are limited to
50 participants.
To register your
interest contact cesrd@nuigalway.ie.
UK:
Dementia in the media this week
1. ÔDementia becomes leading cause of death for Australian
women
Worldwide: General news
1. ÔWhy We Should All Beware The Financial Costs Of
Dementia
2. New edition of
Alzheimer Europe magazine
Alzheimer
Europe has published the 25th edition of its ÔDementia in EuropeÕ
magazine.
To buy the
magazine please see http://alzheimer-europe.org/Publications/E-Shop/Dementia-in-Europe-magazine/Dementia-in-Europe-Magazine-issue-25-October-2017
3. AxovantÕs experimental AD drug fails
ÔAxovant
Sciences, a clinical-stage biopharmaceutical company developing novel
therapeutic solutions to treat dementia, announced results of its MINDSET Phase
3 clinical trial for the treatment of mild to moderate AlzheimerÕs disease.
This
Phase 3 study was a randomised, double-blind, placebo-controlled trial
evaluating the efficacy, safety and tolerability of intepirdine as an
adjunctive therapy to donepezil in people with mild to moderate AlzheimerÕs
disease.
Although
the drug was well tolerated, it failed to demonstrate a statistically significant
improvement in cognition and measures in daily activities at 24 weeks compared
to participants treated with placebo.
Currently,
the company is advancing the HEADWAY Phase 2 trial evaluating intepirdine in
people with dementia with Lewy Bodies. The results are expected at the end of
the yearÕ (Alzheimer Europe).